Effectiveness of subcutaneous monoclonal antibody treatment in emergency department outpatients with COVID-19
Description
CONCLUSIONS: Among ED patients who presented for symptomatic COVID-19 during the Delta variant phase, ED subcutaneous casirivimab/imdevimab treatment was not associated with a decrease in hospitalizations. However, treatment was associated with lower
